Retatrutide — All Topics
Retatrutide topics: mechanism, trials, dosing, safety, and access.
A directory of retatrutide topics. For the definition and science, start with what retatrutide is; choose a practical question below.
Retatrutide at a glance
| Reference | Detail |
|---|---|
| Development code | LY3437943 |
| Sponsor | Eli Lilly |
| Receptor targets | GIP, GLP-1 and glucagon |
| Status | Investigational; see dated filing and approval milestones |
| Informal name | Often called GLP-3; this is not an approved brand name |
Choose your next question
- What have the trials reported? Study populations, endpoints and sources.
- Is a study recruiting near me? Official registry listings and site contacts.
- What does access cost? Retail pricing uncertainty, trial access and expanded access.
- What are the safety concerns? Adverse-event evidence and its limits.
- What can I expect from the results? Why trial averages are not individual forecasts.
- What can I eat when appetite is low? Recipes and smaller-portion ideas.
Browse retatrutide
18 articles
Can You Build Muscle on Retatrutide?
Clinical evidence does not establish retatrutide as a muscle-building treatment. How to interpret lean-mass results and transformation claims.
Updated September 8, 2026
How Does Retatrutide Work? Mechanism of Action Explained
How the three receptors work, and where proposed mechanisms go beyond demonstrated human effects.
Updated September 8, 2026
Mazdutide vs Retatrutide: Dual vs Triple Agonist Data 2026
How the triple agonist retatrutide compares to the dual agonist mazdutide on weight loss, diabetes, and liver fat data.
Updated September 8, 2026
Microdosing Retatrutide & GLP-1 Drugs: What the Research Shows
Current evidence on sub-therapeutic dosing and dose-splitting of GLP-1 receptor agonists.
Updated October 5, 2026
Retatrutide and Alcohol: What We Know
Semaglutide alcohol-use trials are promising but do not establish safe drinking or liver protection with retatrutide.
Updated September 8, 2026
Retatrutide and Pregnancy: Safety, Contraception and Planning
No validated retatrutide pregnancy washout exists. What human observations, animal models and other product labels can tell us.
Updated September 8, 2026
Retatrutide Brand Name: What Will It Be Called?
No announced commercial brand name identified. Retatrutide and LY3437943 refer to the investigational molecule; naming and approval dates remain unconfirmed.
Updated September 8, 2026
Retatrutide Half-Life: How Long Does It Stay in Your System?
Retatrutide has a ~6-day half-life achieved through fatty acid albumin binding — comparable to semaglutide (~7 days) and tirzepatide (~5 days).
Updated October 2, 2026
Retatrutide Pill vs Injection: Is There an Oral Formulation?
Retatrutide has no approved pill or injection. Foundayo and oral Wegovy are different approved medicines.
Updated September 8, 2026
Retatrutide Statistics & Trial Data
The citable data hub — retatrutide weight-loss and safety figures by dose, with a primary source on every number.
Updated October 1, 2026
Retatrutide vs CagriSema (Cagrilintide + Semaglutide): Triple Agonist vs Amylin + GLP-1 Combo
Compare retatrutide with the cagrilintide–semaglutide combination, including REDEFINE 4 and why separate trial results do not establish superiority.
Updated September 8, 2026
Retatrutide vs Mounjaro vs Ozempic
Mounjaro and Ozempic are diabetes brands; Zepbound and Wegovy have weight-management indications. Compare their evidence with investigational retatrutide.
Updated September 8, 2026
Retatrutide vs Orforglipron: Injectable Triple Agonist vs Oral GLP-1
Foundayo (orforglipron) is FDA-approved; retatrutide is investigational. Compare their routes, trial evidence, and safety limits.
Updated September 8, 2026
Retatrutide vs Survodutide
Two next-generation obesity drugs that both include glucagon agonism — how the triple and dual agonist approaches compare.
Updated September 8, 2026
Retatrutide vs Tirzepatide (Zepbound): Triple Agonist vs Dual Agonist
How retatrutide and tirzepatide differ in receptor activity, trial evidence, safety, and approval status. Direct TRIUMPH-5 results are pending.
Updated September 8, 2026
Retatrutide vs Wegovy: Triple Agonist vs GLP-1
Wegovy is approved in oral and injectable forms, including Wegovy HD. Retatrutide remains investigational with no completed direct comparison.
Updated September 8, 2026
Retatrutide vs Zepbound: What's the Difference?
Zepbound is an approved tirzepatide treatment. Retatrutide remains investigational; separate trial results do not prove a treatment advantage.
Updated September 8, 2026
What Is Retatrutide (GLP-3)?
Eli Lilly’s investigational triple receptor agonist: how it works, what trials show, and why GLP-3 is an informal nickname.
Updated September 8, 2026